Document:

Exhibit 4.2       Restated Bylaws
                  Section 1 regarding voting of shares.

                                    ARTICLE I
                        SHAREHOLDERS: MEETING AND VOTING

1.1      Place of Meetings.

         Meetings of the shareholders shall be held at the corporation's
principal office, or at such other location as shall be designated in the notice
of meeting.

1.2      Annual Meetings.

         The annual meeting of the shareholders shall be held on the first
Monday of July of each year, if not a legal holiday, and if a legal holiday,
then on the next succeeding business day, at the hour of 2:00 o'clock, p.m. The
time and date of such meeting may be varied by the Board of Directors provided
that notice of the varied date and time of the annual meeting is given in
accordance with these By-Laws. At the annual meeting, the shareholders shall
elect by vote a Board of Directors, consider reports of the affairs of the
corporation, and transact such other business as may properly be brought before
the meeting.

1.3      Special Meetings.

         Special meetings of the shareholders may be called at any time by the
President, the Board of Directors, by the holders of not less than one-tenth
(1/10th) of all the shares entitled to vote at such meeting, and as otherwise
provided in the Nevada Business Corporation Act, as amended (the "Act").

1.4      Notice of Meetings.

         1.4.1 Written or printed notice, in a comprehensible form, stating the
date, time and place of the meeting, and in case of a special meeting, a
description of the purpose or purposes for which the meeting is called, shall be
delivered not earlier than sixty (60) nor less than ten (10) days before the
meeting date, in person, telegraph, teletype, or other form of wire or wireless
communication, by mail or private carrier, by or at the direction of the
President, Secretary, other officer or persons calling the meeting. If mailed,
the notice is effective when deposited postpaid in the United States mail,
correctly addressed to the shareholder's address shown on the Corporation's
current record of shareholders. In all other cases, the notice shall be
effective when received by the shareholders.

         1.4.2 If a shareholders' meeting is adjourned to a different date, time
or place, notice need not be given of the new date, time or place, if the new
date, time or place is announced at the meeting before adjournment, unless a new
record date for the adjourned meeting is or must be fixed under the Act, in
which event notice of the adjourned meeting must be given to the persons who are
shareholders as of the new record date.

1.5      Voting Entitlement of Shares.

         Unless the Articles of Incorporation provide otherwise, or except as
provided by the Act, each outstanding share, regardless of class, is entitled to
one vote on each matter voted on at a shareholders' meeting. Only shares are
entitled to vote.

                                       -8-
<PAGE>
1.6      Quorum and Voting.

         1.6.1 Shares entitled to vote as a separate voting group may take
action on a matter at a meeting only if a quorum of those shares exists with
respect to that matter. Unless the Articles of Incorporation or the Act provides
otherwise, a majority of the votes entitled to be cast on the matter by the
voting group constitutes a quorum of that voting group for action on that
matter.

         1.6.2 Once a share is represented for any purpose at a meeting, it is
deemed present for quorum purposes for the remainder of the meeting and for any
adjournment of that meeting, unless a new record date is or must be set for that
adjourned meeting.

         1.6.3 If a quorum exists, action on a matter, other than the election
of directors, by a voting group, is approved if the votes cast within the voting
group favoring the action exceed the votes cast opposing the action, unless the
Articles of Incorporation or the Act requires a greater number of affirmative
votes.

         1.6.4 Unless otherwise provided in the Articles of Incorporation,
Directors are elected by a plurality of the votes cast by the shares entitled to
vote in the election at a meeting at which a quorum is present.

         1.6.5 If the Articles of Incorporation or the Act provides for voting
by a single group on a matter, action on that matter is taken when voted upon by
that voting group in accordance with these By-Laws.

         1.6.6 If the Articles of Incorporation or the Act provides for voting
for two or more voting groups on a matter, action on that matter is taken only
when voted upon by each of those voting groups counted separately as provided by
these By-Laws.

1.7      Proxies.

         A shareholder may vote shares in person or by written proxy signed by
the shareholder or the shareholder's attorney in fact and delivered to the
secretary or other officer or agent of the Corporation authorized to tabulate
votes.

1.8      Record Date.

         The record date for determining the shareholders entitled to notice of
a shareholders' meeting, to demand a special meeting, to vote or to take other
action, shall, unless otherwise determined by the Board of Directors in advance
of such action, be the date of such notice, demand, vote, or other action.

1.9      Shareholders' List for Meeting.

         After fixing a record date for a meeting, the corporation shall prepare
an alphabetical list of the names of all of its shareholders who are entitled to
notice of a shareholders' meeting. The list must be arranged by voting group,
and within each voting group by class or series of shares, and show the address
of and number of shares held by each shareholder. The shareholders' list must be
available for inspection by any shareholder, beginning two business days after
notice of the meeting is given for which the list was prepared and continuing
through the meeting, at the corporation's principal office or at a place
identified in the meeting notice in the city where the meeting is to take place.
The corporation shall make the shareholders' list available at the meeting, and
any shareholder, the shareholder's agent, or attorney is entitled to inspect the
list at any time during the meeting or any adjournment thereof.

                                      -9-<PAGE>
                                                                   Exhibit 10.21

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                            Under 17 C.F.R. (S)(S) 200.80(b)(4),
                                                            200.83 and 240.24b-2

                 MONONUCLEAR CELL COLLECTION SERVICES AGREEMENT

                                                                OCTOBER 22, 2001

     This Mononuclear Cell Collection Services Agreement (the "Agreement") is
made as of the Effective Date, as that date is defined herein, by and between
Dendreon Corporation, a Delaware corporation with offices located at 3005 First
Avenue, Seattle, Washington, 98121, and Gambro Healthcare, Inc., a Tennessee
corporation with offices located at 10810 W. Collins Avenue, Lakewood, Colorado,
80215.

                              Preliminary Statement

     A.   Dendreon is engaged in the development of therapeutic vaccines that
          stimulate a patient's immunity. Provenge is a therapeutic vaccine for
          the treatment of prostate cancer and is currently in Phase III
          clinical trials. Other Dendreon cancer vaccines are in earlier stages
          of development.

     B.   As the first step in the manufacture of a vaccine, a patient undergoes
          a cell collection to collect, isolate and retain the mononuclear cells
          that are raw material for the vaccine.

     C.   Gambro provides fixed site and mobile renal dialysis and cell
          collection services throughout the United States, and is an affiliate
          of Gambro BCT, a manufacturer of cell collection and related
          equipment.

     D.   Dendreon and Gambro wish to enter into an agreement by which Gambro
          will provide mononuclear cell collection for the manufacture of
          Provenge following its approval by the Food and Drug Administration
          ("FDA"), and provide cell collection for Dendreon vaccines that may be
          approved by the FDA thereafter.

     Based upon the foregoing, the parties agree as follows:

                                    Agreement

1.   Definitions. The following words shall have the following meanings as used
     in this Agreement.

     1.1  "Affiliate" means any corporate entity, partnership or other business
          entity which is under common control with, is controlled by, or
          controls, a Party. The word and root "control" means:

          1.1.1 for any corporate entity, direct or indirect ownership of at
                least fifty percent (50%) of the stock or participating shares
                entitled to

<PAGE>

                vote in an election for members of the board of directors of
                such entity; and

          1.1.2 for any partnership, the power customarily held by a general
                partner to direct the management and policies of such
                partnership; and

          1.1.3 for any other business entity, the right to receive at least
                fifty percent (50%) of the net profit of such business entity;
                and

          1.1.4 for any foreign entity, if the maximum permitted percentage in
                1.1.1 or 1.1.3 is less than fifty percent, then that alternative
                percentage applies to 1.1.1 and 1.1.3.

     1.2  "Best Practices" means practices that fully comply with good medical
          practice, Food and Drug Administration ("FDA") rules and guidances,
          and all other applicable federal, state and local rules and
          regulations.

     1.3  "cGTP" means the FDA's current Good Tissue Practices, including the
          registration regulations codified in 21 CFR Part 207, as proposed or
          as in effect and as amended from time to time.

     1.4  "Commencement Date" means the date of approval by the FDA of a
          Biologics License Application for Provenge. The Commencement Date is
          currently expected to occur in the second quarter of 2003.

     1.5  "Confidential Information" means information owned or possessed by the
          disclosing Party, including methods, techniques and processes, and
          technical and scientific data, unpublished findings, biological
          material, know-how, specifications, patents, patent applications,
          algorithms, programs, designs, drawings, and formulae, and
          engineering, manufacturing, marketing, financial and business plans
          and data. It may also be information other than that which derives
          actual or potential economic value from not being generally known to
          or accessible by proper means by other persons who can gain economic
          value from it.

     1.6  "Dendreon" means Dendreon Corporation and its Affiliates.

     1.7  "Dendreon Technology" means Dendreon patents, patent applications,
          know-how, methods, techniques and processes, technical and scientific
          data, specifications, algorithms, programs, designs, drawings,
          formulae, engineering and manufacturing information, works of
          authorship, whether or not copyrightable, patentable or susceptible to
          other form of legal protection. Dendreon Technology, includes, but is
          not limited to the identification and isolation of tumor antigens, the
          isolation of dendritic cell precursors, the manipulation of dendritic
          cell precursors and dendritic cells, antigen delivery cassettes,
          vaccine manufacture and cancer treatment.

     1.8  "Effective Date" means the date of the last signature to this
          Agreement.

                                        2

<PAGE>

     1.9  "Gambro" means Gambro Healthcare, Inc. and its Affiliates.

     1.10 "Gambro Technology" means Gambro patents, patent applications,
          know-how, methods, techniques and processes, technical and scientific
          data, specifications, algorithms, programs, designs, drawings,
          formulae, engineering and manufacturing information, works of
          authorship, whether or not copyrightable, patentable or susceptible to
          other form of legal protection. Gambro Technology, includes but is not
          limited to the procedures and equipment for mononuclear cell
          collection and re-infusion.

     1.11 "Party" or "Parties" means Gambro or Dendreon or both of them as the
          context requires.

     1.12 "Patient" means a person receiving a Vaccine whose principal place of
          residence is within fifty (50) linear miles of one or more Sites.

     1.13 "Renewed Term" shall have the meaning set forth in Section 12.1 of
          this Agreement.

     1.14 "Services" shall mean mononuclear cell collection and all services
          associated therewith, but not including Vaccine infusion.

     1.15 "Site" means a facility providing mononuclear cell collection services
          under this Agreement.

     1.16 "Term" shall have the meaning set forth in Section 12.1.

     1.17 "Vaccine" means a Dendreon therapeutic vaccine approved by the FDA.

2.   Services.

     2.1  Services. Beginning on the Commencement Date and for the Term and any
          Renewed Term of this Agreement, Dendreon agrees to make commercially
          reasonable efforts to refer no less that seventy percent (70%) of all
          Patients to Gambro for Services and Gambro agrees to provide Services
          to all Patients and other persons referred to it, on the terms and
          conditions set forth in this Agreement. The Services shall not be
          adversely affected by any other cell collection services provided at
          any Site.

     2.2  Primary Vendor Relationship. During the Term of this Agreement and any
          Renewed Term, Gambro shall be a primary vendor of Services to
          Dendreon. Dendreon shall use commercially reasonable efforts to offer
          to Gambro the opportunity to operate no less than seventy percent
          (70%) of cell collection sites in the United States.

                                        3

<PAGE>

     2.3  [...***...]

     2.4  [...***...]

     2.5  Notice of Prospective Vaccine Approval. Within thirty (30) days after
          filing a Biologics License Application for a Vaccine, Dendreon shall
          provide Gambro with written notice of the filing, its estimate of the
          likely date of FDA approval of the Vaccine, and its estimate of the
          volume of cell collections expected during the first twenty-four (24)
          months following approval of the Vaccine.

3.   Standards of Service. Gambro shall adhere to the following standards in
     providing the Services under this Agreement.

     3.1  Standards of Care. Gambro shall adhere to Standards of Care conforming
          to Best Practices in providing the Services. The Standards of Care
          shall be developed by Gambro and approved by Dendreon, in its sole
          discretion, in advance of implementation. An initial draft of such
          Standards of Care shall be provided to Dendreon for review on or
          before January 2, 2002, and the Standards of Care shall be submitted
          in final form to Dendreon for approval on or before March 31, 2002.
          Upon approval, the Standards of Care shall be attached to this
          Agreement as Appendix A and incorporated herein by reference. The
                       ----------
          Standards of Care shall address, without limitation, the following:

          3.1.1 the protocol for mononuclear cell collection for Vaccines
                modeled upon the Gambro COBE Spectra "AutoPBSC" protocol for
                mononuclear cell collection;

          3.1.2 physician supervision, physician and licensed staff training,
                and standards for compliance with state facility and medical
                licensure requirements;

          3.1.3 cell collection from sero positive patients (to be identified to
                Gambro prior to cell collection or re-infusion);

          3.1.4 physical facility and equipment standards; and

          3.1.5 required data, reports and documentation

     3.2  Emergency Procedures. Gambro shall adhere to Emergency Procedures
          conforming to Best Practices for response to adverse events and
          medical emergencies. The Emergency Procedures shall be developed by
          Gambro and approved by the Parties prior to implementation. An initial
          draft of such Emergency Procedures shall be provided to Dendreon for
          review on or before January 2, 2002 and the Emergency Procedures shall
          be submitted to Dendreon in final form no later than March 31, 2002.
          Upon approval by both Parties, the Emergency Procedures shall be
          attached to this Agreement as Appendix B and incorporated herein by
                                        ----------
          reference. The Emergency

                                               *Confidential Treatment Requested

                                        4

<PAGE>

          Procedures shall address, without limitation, required site equipment
          such as crash carts and defibrillators.

     3.3  Patient Service Standards. Gambro shall adhere to Patient Service
          Standards conforming to Best Practices. The Patient Service Standards
          shall be developed by Gambro and approved by Dendreon, in its sole
          discretion, prior to implementation. An initial draft of the Patient
          Service Standards shall be provided to Dendreon for review on or
          before January 2, 2002, and the final Patient Service Standards shall
          be submitted for approval to Dendreon no later than March 31, 2002.
          Upon approval, the Patient Service Standards shall be attached to this
          Agreement as Appendix C and incorporated herein by reference. The
                       ----------
          Patient Service Standards shall address, without limitation:

          3.3.1 standard operating hours of 6:00am to 9:00pm six (6) days per
                week and "on-call" service;

          3.3.2 protocols for communications between Gambro and Dendreon and
                Gambro and patients;

          3.3.3 staffing levels;

          3.3.4 master schedule compliance in order to insure, among other
                things, that all cell collections are performed by Gambro within
                three (3) working days of notice from Dendreon at the Site
                designated by Dendreon;

          3.3.5 best efforts to schedule two or more collections for the same
                time period at a given Site;

          3.3.6 release of cell collections within thirty (30) minutes of the
                completion of the cell collection process;

          3.3.7 procedures to insure continued service in the event of the
                temporary closure of a Site; and

          3.3.8 policies and procedures to protect patient privacy as required
                for a "covered entity" by the Health Insurance Portability and
                Accountability Act of 1996, Public Law 104-19 ("HIPAA") and the
                rules in effect there under as of the April 14, 2003 enforcement
                date of the HIPAA privacy regulations.

     3.4  Quality Control Standards. Gambro shall adhere to Quality Control
          Standards conforming to Best Practices. The Quality Control Standards
          shall be approved by Dendreon, in its sole discretion, prior to
          implementation. An initial draft of such Quality Control Standards
          shall be provided to Dendreon on or before January 2, 2002, and the
          final Quality Control Standards shall be submitted to Dendreon for
          approval on or before March 31, 2002. Upon approval, the Quality
          Control Standards shall be attached to this Agreement as Appendix D
                                                                   ----------
          and incorporated herein by reference. The Quality Control Standards
          shall address, without limitation:

                                        5

<PAGE>

          3.4.1 compliance with cGTP as proposed or as hereafter in effect and
                21 CFR 1271 Subparts A and B;

          3.4.2 periodic audits by Gambro of its Sites, equipment, and records;

          3.4.3 lot number and tracking systems controls including, but not
                limited to, bar coding; and

          3.4.4 compliance with FDA facility registration requirements,
                inspections and validations and all other applicable
                regulations, guidances, and directives.

     3.5  Applicability and Amendment to Standards. The Standards of Care,
          Emergency Procedures, Patient Service Standards, and Quality Control
          Standards shall be in effect at each Gambro Site performing cell
          collections under this Agreement. Each may be amended from time to
          time in accordance with Section 36 as necessary or desirable to insure
          the highest level of service and to comply with Best Practices.

     3.6  Adverse Event Reporting. Gambro shall report to Dendreon as soon as
          reasonably practicable any adverse events, as that term is defined by
          FDA regulations, associated with cell collections that are serious,
          new or unexpected events, or events occurring with increased
          frequency. All other adverse event associated with cell collection
          shall be reported to Dendreon in summary format quarterly.

     3.7  Complaints. Gambro shall promptly investigate and respond to any
          complaints that may relate to Services under this Agreement.

4.   Service Sites.

     4.1  Initial Sites. On and after the Commencement Date, Gambro shall
          provide Services for the manufacture of Provenge and thereafter any
          other Vaccine at each of the Sites located in the cities listed on
          Appendix E attached to this Agreement and incorporated by reference.

     4.2  Additional Sites. On written notice, Dendreon may request that Gambro
          add one or more additional sites for cell collection or replace an
          existing operating Site with another site. The notice shall specify
          the reasons for the addition or replacement, and propose a
          commercially reasonable date to begin operations. Within fourteen (14)
          days of receipt of such notice, Gambro shall notify Dendreon whether
          it will add or replace a site as requested. If Gambro declines, then
          such notice shall specify its reasons. An accepted additional or
          replacement site shall be a Site subject to all of the terms and
          conditions of this Agreement. If the parties are unable to reach
          agreement on the replacement of a site, the matter shall be resolved
          through the dispute resolution provisions in Section 24.

                                        6

<PAGE>

     4.3  Site Supervision. Each Site shall be supervised by a Medical Director
          who shall be a physician licensed to practice in the state in which
          the Site is located. The Medical Director shall be responsible for all
          of the operations of the Site, including compliance with the Standards
          of Care, Emergency Procedures, Patient Service Standards, and Quality
          Control Standards at such site.

5.   Implementation Schedule. After the completion of the standards required by
     Sections 3.1 through 3.4, Dendreon and Gambro shall mutually agree to a
     schedule for the establishment and validation of Sites under Section 6, the
     integration of information technology systems under Section 8, and the
     training of licensed staff, technicians, back office personnel and others.
     The implementation schedule shall also provide for one or more tests prior
     to the Commencement Date of the procedures, standards, and practices
     established under this Agreement. The implementation schedule shall take
     into account the then anticipated Commencement Date, and may be adjusted by
     mutual agreement of the parties in light of changes, if any, in such date.

6.   Establishment and Validation. In accordance with the Implementation
     Schedule, representative Sites selected by mutual agreement of Gambro and
     Dendreon shall be fully equipped, staffed, and available for inspection and
     validation by Dendreon and the FDA. As of the Commencement Date, each Site
     listed on Appendix E and each additional Site added thereafter shall be
               ----------
     available for inspection and validation by the FDA and by Dendreon in
     accordance with Section 14. All Sites shall at all times conform to all the
     rules, guidances and directives of the FDA, and all other federal, state,
     and local laws and requirements.

7.   Personnel. The Services shall be performed and/or supervised as required by
     state law and standards of medical practice by appropriately licensed
     personnel employed by Gambro. Gambro shall insure that all such personnel
     (i) are appropriately licensed in the jurisdiction in which the Site is
     located, (ii) are appropriately trained in accordance with the
     specifications developed under Section 13 to perform the required
     procedures and respond to adverse events or emergencies; and (iii) do not
     present an inappropriate risk to patients.

8.   Information Technology. Gambro shall take such steps as may be necessary or
     desirable to insure that its information technology systems are capable of
     transferring information to and integrating with the information technology
     systems that Dendreon shall have as of the Commencement Date. On or before
     March 31, 2002, Gambro and Dendreon shall develop a mutually acceptable
     plan for information technology, including, but not limited to process
     notification, scheduling, data collection, and integration of their
     respective information technology systems. All Gambro and Dendreon
     information technology systems shall conform to the privacy requirement for
     a "covered entity" under HIPAA and the rules in effect from time to time
     there under as of the April 14, 2003

                                        7

<PAGE>

     enforcement date of the HIPAA privacy regulations. The integration of the
     information technology systems shall occur in accordance with the
     implementation schedule established under Section 6.

9.   Payment.

     9.1  Payment Amount. From the Commencement Date until the [...***...],
          Dendreon shall pay Gambro the "Base Price" of [...***...] per cell
          collection procedure. Thereafter, the Base Price shall be adjusted
          [...***...] to account for [...***...] in accordance with Appendix F
                                                                    ----------
          where the designation [...***...] refers to the [...***...] following
          the Commencement Date. During the Renewed Term, if any, the payment
          per cell collection shall be the [...***...], adjusted during the
          Renewed Term by the CPI as provided in Section 9.3 below.

     9.2  Adjustment to Appendix F. If, during any calendar year, Dendreon
          [...***...], Gambro may, within [...***...], notify Dendreon in
          writing of its intent to seek adjustment to the [...***...] set forth
          in Appendix F. In that event, the Parties will promptly meet to
             ----------
          negotiate such adjustments. The negotiations will consider, among
          other factors, [...***...]. The [...***...] upon a determination that
          Gambro, [...***...]. Any agreed adjustments to Appendix F shall be
                                                         ----------
          effective only on and after the date of agreement to such adjustments.
          If the Parties are unable to agree to adjustments, then either Party
          may elect to proceed under the dispute resolution provisions of
          Section 24. Both Parties acknowledge and agree that this Section 9.2
          is not intended to and does not provide any right to seek adjustment
          to the Base Price or to the CPI under Section 9.3, or to adjust upward
          the premium above the Base Price paid to Gambro for volumes below the
          Base Price volumes as set forth on Appendix F.
                                             ----------

     9.3  CPI Adjustment. The Base Price shall also be adjusted each calendar
          year in advance commencing with the first January 1 following the
          Commencement Date. As of January 1 of each year, the Base Price shall
          be the Base Price during the calendar year which immediately preceded,
          increased by the percentage by which the Consumer Price Index for All
          Urban Consumers for All Items CPI-U (1982-84=100) may have increased
          during the preceding calendar year.

     9.4  Invoices. Within thirty (30) days of the end of each calendar month,
          Gambro shall submit to Dendreon an invoice for the cell collections
          performed during that calendar month, itemized by Site and by patient.
          Payment shall be made by Dendreon [...***...] thereafter at the Base
          Price of [...***...] per cell collection. At the end of each calendar
          quarter, Dendreon shall [...***...]. Dendreon agrees to pay Gambro
          Healthcare interest at the rate of [...***...] per month on any
          amounts remaining unpaid after [...***...].

                                               *Confidential Treatment Requested
                                        8

<PAGE>

     9.5  Unused Vaccines, Incomplete Procedures, Emergency Procedures.

          9.5.1 If, for any reason not attributable to Gambro, a cell collection
                terminates after it has begun but before completion or a patient
                does not receive an infusion of Vaccine manufactured from a
                completed cell collection, then Dendreon shall pay Gambro
               [...***...] contemplated in Section 9.1 herein.

          9.5.2 If, for any reason not attributable to Gambro, such as a failure
                of the patient to meet patient criteria, a cell collection is
                cancelled after the patient has arrived at the Site but before
                the cell collection begins, then Dendreon shall pay Gambro
                [...***...] of the payment contemplated in Section 9.1 herein.

          9.5.3 If, for any reason attributable in whole or in material part to
                Gambro, a cell collection is cancelled after it begins or a
                Vaccine cannot be manufactured from a patient's collected cells,
                Gambro shall receive [...***...]. Dendreon shall report to
                Gambro any cell collections subject to this Section in
                connection with its quarterly payment to Gambro.

          9.5.4 If Gambro fails to comply with the Emergency Procedures
                established under Section 3.2 in any material respect, the
                payment to Gambro for any cell collection associated with such
                failure shall be reduced by [...***...].

          9.5.5 If Dendreon makes a payment to which Gambro is not entitled
                under this Section 9.5, then Dendreon shall deduct the amount of
                such payment from the amount due to Gambro at the end of the
                next calendar quarter. Cell collections subject to this section
                shall be included in the volume totals for each quarter.

          9.5.6 In addition to the reductions provided for in this Section 9.5
                Gambro may be required to pay certain assessments for
                noncompliance with performance standards as set forth in
                Appendix G and incorporated herein by reference.
                ----------

     9.6  Records. Gambro shall keep and maintain for the Term and any Renewed
          Term and for a period of five (5) years thereafter (or for such longer
          period as may be required by cGTP or other law or regulation) accurate
          and complete accounting information, reports and other records
          (together with supporting documentation) relating to the performance
          of its obligations under this Agreement for the proper determination
          and computation of payments, and verification of its performance under
          this Agreement. Upon Dendreon's request, Gambro shall promptly provide
          copies of such records relating to payments under this Agreement. The
          cost of producing such copies shall be borne by Dendreon.

10.  Gambro's Representations and Warranties. Gambro covenants, represents and
     warrants as follows:

                                               *Confidential Treatment Requested
                                        9

<PAGE>

          a.   Gambro is a corporation organized under the laws of the State of
               Tennessee and has all necessary rights, powers, licenses,
               certifications, and authorities to enter into this Agreement.

          b.   Gambro's performance under this Agreement does not conflict with
               or create a breach or a default of any law, order of a court or
               government agency, contract, or other obligation with any third
               party.

          c.   Gambro shall at all times conform to Best Practices in performing
               under this Agreement.

          d.   Gambro shall at all times conform to the rules and guidances of
               the FDA governing cGTP.

          e.   Gambro shall at all times employ its best efforts to comply with
               the privacy requirements for a "covered entity" under HIPAA
               (after the April 14, 2003 enforcement date of the HIPAA privacy
               regulations) and the rules there under and with all state privacy
               statute and regulations in effect in each state in which it
               provides Services under this Agreement.

          f.   During the Term and any Renewed Term, Gambro shall not enter into
               any agreement or arrangement with any other entity that would
               negatively impact Gambro's ability to perform the Services for
               Dendreon.

          g.   During the Term of this Agreement, Gambro shall maintain the
               capacity to provide all Services required by Dendreon.

11.  Dendreon's Representations and Warranties. Dendreon covenants, represents
     and warrants as follows:

          a.   Dendreon is a corporation organized under the laws of the state
               of Delaware, and has all necessary rights, powers and authorities
               to enter into this Agreement.

          b.   Dendreon's performance under this Agreement does not conflict
               with or create a breach or a default of any law, order of a court
               or government agency, contract, or other obligation with any
               third party.

          c.   Dendreon shall at all times employ its best efforts to comply
               with the privacy requirements for a "covered entity" under HIPAA
               (after the April 14, 2003 enforcement date of the HIPAA privacy
               regulations) and the rules there under and with all state privacy
               statute and regulations in effect in each state in with Gambro
               provides Services under this Agreement.

          d.   Dendreon shall at all times conform to the rules and guidances of
               the FDA governing cGTP.

          e.   Dendreon shall at all times conform to Best Practices in
               performing under this Agreement.

12.  Term and Termination.

     12.1 Term. The term ("Term") of this Agreement shall be five years from the
          first full calendar quarter following the Commencement Date. Upon the
          expiration of the Term, this Agreement shall automatically renew for
          an

                                       10

<PAGE>

          additional five year term (the "Renewed Term") unless, no more than
          four (4) calendar quarters and no less than two (2) calendar quarters
          before the end of the Term, either Party provides written notice to
          the other of intent to terminate this Agreement.

     12.2 Windup Upon NonRenewal. If either Party elects to terminate this
          Agreement pursuant to Section 12.1 then the Term of this Agreement
          shall be extended for a period of six months (the "Extended Term").
          During the Extended Term, the Parties shall work together
          cooperatively and in good faith to windup their business relationship,
          transfer cell collection responsibilities to those providers as may be
          designated by Dendreon, comply with regulatory requirements applicable
          to the termination, and otherwise complete an orderly termination.
          During the Extended Term, Gambro shall continue to provide Services to
          all patients referred by Dendreon, but Dendreon shall not be required
          to comply with the seventy percent (70%) minimums in Sections 2.1 and
          2.2, or with the restrictions and [...***...]. During the Extended
          Term, Gambro shall not be required to comply with the restrictions and
          [...***...] of Section 2.4. The Parties also may agree to modify other
          provisions of this Agreement to facilitate an orderly termination.
          Except as the Parties may so agree or as expressly provided in this
          Section 12.2, all of the terms and conditions of this Agreement shall
          remain in full force and effect during the Extended Term.

     12.3 Termination for Delay of the Commencement Date. If for any reason the
          Commencement Date is delayed beyond [...***...], then Dendreon or
          Gambro may terminate this Agreement on sixty (60) days written notice
          to the other Party.

     12.4 Termination for Material Breach. Notwithstanding the Term or Renewed
          Term, this Agreement may be terminated if either Party materially
          breaches this Agreement and such breach (i) is not cured within thirty
          (30) days of written notice if such breach is caused by the failure of
          a Party to meet its financial obligations under this Agreement; or
          (ii) is not cured within sixty (60) days of written notice if such
          breach relates to any other obligation under this Agreement. In either
          case, the notice shall detail the nature of the breach. A Party
          disputing the existence of a material breach or the failure to cure an
          alleged breach may elect to proceed under the dispute resolution
          provision of Section 24. If a Party elects to proceed under Section 24
          within fifteen (15) days of the end of the thirty (30) day or sixty
          (60) day cure period, as the case may be, this Agreement shall remain
          in effect until the dispute resolution process is completed (excluding
          any appeals); provided that, in the event of an arbitration, the
          arbitrator shall be empowered to grant appropriate temporary relief
          that, in light of the nature of the dispute, modifies obligations or
          imposes additional conditions on the performance of either Party under
          this Agreement.

                                               *Confidential Treatment Requested
                                       11

<PAGE>

     12.5 Patient Care. In the event of expiration or earlier termination of
          this Agreement, Gambro agrees to use every reasonable effort to insure
          that scheduled cell collections are completed. Both parties shall use
          their best efforts to effectuate an efficient transfer of cell
          collection to another provider.

     12.6 Payment after Termination. Termination shall not relieve Gambro
          Healthcare or Dendreon from their continuing obligations under this
          Agreement as set forth in Section 39, and shall not relieve Dendreon
          from any obligations under Section 9 to pay Gambro for services
          rendered hereunder prior to termination of this Agreement

13.  Training. On or before March 31, 2002, Gambro shall develop training
     programs for its licensed and non-licensed staff that, in addition to
     training in mononuclear cell collection, will train staff in the standards
     developed by Gambro under Section 3. The training programs shall be
     approved by Dendreon in its sole discretion prior to implementation. Except
     in unusual circumstances, no staff member shall be assigned to provide
     services to Dendreon or cell collection services under this Agreement
     before receiving such training.

14.  Audits and Inspections. Upon fourteen (14) days prior written notice from
     Dendreon, Gambro shall permit Dendreon, or an independent third party
     appointed by Dendreon, to inspect any Site providing services under this
     Agreement, including a facility providing centralized non-medical services
     such as data management, accounting or inventory management, or to audit
     any and all of the systems, procedures, records and results under this
     Agreement. Dendreon shall promptly provide Gambro with a report of any
     deficiencies identified in such audit or inspection and Gambro shall have
     thirty (30) days thereafter to bring any identified deficiency into full
     compliance. Any such inspection or audit shall be conducted during regular
     business hours and shall use its best efforts not to unduly interfere with
     any of Gambro's operations or disturb any of Gambro's patients.

15.  Relationship Management. Gambro and Dendreon shall each appoint an
     individual as relationship manager who shall have primary responsibility
     for that Party for this Agreement. Such person may be replaced by the
     appointing Party in its discretion on ten (10) working days notice to the
     other Party. The appointed persons shall each be responsible for
     coordinating activities under this Agreement within their respective
     organizations. All communications regarding performance under this
     Agreement shall be addressed to the respective relationship managers of the
     Parties. Any amendment to this Agreement shall require the signature of the
     then relationship manager of each of the Parties, as acknowledgment of the
     modification.

16.  Prospective Events. Two classes of prospective events are covered by this
     Section. The first are any state or federal statutes or common laws, or
     state or

                                       12

<PAGE>

     federal administrative agency rules, guidances or directives now existing
     or enacted or promulgated after the Effective Date of this Agreement that
     are interpreted by judicial decision, a regulatory agency or legal counsel
     in such manner as to indicate that the structure of this Agreement, or any
     act or service required of Gambro or Dendreon hereunder is in violation of
     such laws, rules, guidances or directives ("Prospective Illegality") The
     second is the enactment of a state or federal statute, common law, state or
     federal administrative agency rule, guidance or directive after the
     Effective Date and not contemplated before the Effective Date for which
     compliance by Gambro imposes an extraordinary and unanticipated financial
     burden that is generally applicable to all providers of cell collections
     services for the manufacture of biologics ("Prospective Cost Increase"). In
     the event of a Prospective Illegality, Gambro and Dendreon shall amend this
     Agreement as necessary to comply with such laws, rules, guidances or
     directives including, without limitation, amendments relieving either Party
     from the obligation to perform an act. Pending agreement on the appropriate
     amendment(s) to this Agreement, either Party, on fourteen (14) days notice
     to the other Party, may cease to perform a questioned act; provided,
     however, that this Agreement will nevertheless be performed by both Parties
     to the extent possible. In the event of a Prospective Cost Increase, the
     parties shall negotiate amendments to the payment terms of this Agreement.
     Pending agreement on the appropriate amendment(s), this Agreement will
     continue to be performed by both parties. To the maximum extent possible,
     any such amendment(s) agreed to under this Section 14 shall preserve the
     primary benefits sought to be achieved by this Agreement and the underlying
     economic and financial arrangements between the Parties. If the Parties
     agree that the primary benefits sought to be achieved by this Agreement
     cannot be achieved through an appropriate amendment, then this Agreement
     will be terminated one hundred eighty (180) days thereafter. If the Parties
     are unable to agree to amendment(s) as required by this Section, the matter
     shall be submitted to dispute resolution in accordance with Section 24,
     below.

17.  Indemnification by Gambro. Gambro shall defend, indemnify and hold harmless
     Dendreon and its directors, officers, employees, and agents from any and
     all claims, costs, damages, expenses, fees, injuries, liabilities and
     losses including reasonable attorneys' fees (collectively "Losses") arising
     out of any and all governmental or third party actions relating to:

          a.   a breach by Gambro of its representations and warranties;

          b.   a failure by Gambro to comply with Best Practices;

          c.   the manufacture, design, use, storage, distribution, promotion,
               marketing, sale or failure of any kind of equipment used by
               Gambro to perform cell collections or any other services
               hereunder;.

          d.   any actual or alleged injury, damage, death or other consequence
               occurring to any person or property as a result of the negligence
               or willful act, including acts of omission, of Gambro or any
               officer, director, employee, or agent of Gambro performed under
               this Agreement.

          e.   Gambro's breach of any provision of this Agreement.

                                       13

<PAGE>

          f.   any claim for infringement of a patent or other intellectual
               property arising out of the Gambro Technology or apparatus
               originating with Gambro BCT.

     Provided, however, that Gambro shall have no obligation to indemnify
     Dendreon or its directors, officers, employees or agents to the extent of
     the Losses, if any, that are caused by conduct of Dendreon, its officers,
     directors, employees, agents as described in Section 18(a)-18(e).

18.  Indemnification by Dendreon. Dendreon shall defend, indemnify and hold
     harmless Gambro and its officers, directors, employees, and agents from any
     and all claims, costs, damages, expenses, fees, injuries, liabilities and
     losses, including reasonable attorneys' fees (collectively "Losses")
     arising out of any and all government or third party actions relating to:

          a.   a negligent or willful act by Dendreon relating to this
               Agreement, including acts of omission.

          b.   a breach by Dendreon of its representations and warranties.

          c.   a failure by Dendreon to comply with federal, state or local laws
               or regulations or other requirements applicable to its vaccines,
               including regulatory requirements of the FDA.

          d.   any actual or alleged injury, damage, death or other consequence
               occurring to any person or property as a result, direct or
               indirect of a Vaccine.

          e.   Any claim for infringement of a patent or other intellectual
               property arising out of the Dendreon Technology.

     Provided, however, that Dendreon shall have no obligation to indemnify
     Gambro or its directors, officers, employees or agents for the Losses, if
     any, that result from conduct of Gambro or its directors, officers,
     employees and agents as described in Section 17(a) through 17(f).

19.  Indemnity Procedures. Upon becoming aware of any potential claim, the
     indemnified Party shall promptly provide written notice to the indemnifying
     Party. Delay in providing such notice shall relieve the indemnifying Party
     from the obligation to indemnify only if the delay materially impairs the
     indemnifying Party's defense. The indemnifying Party shall assume control
     of the defense of the claim at its own expense and any attorneys' fees and
     costs incurred thereafter by the indemnified Party shall not be subject to
     indemnification. If the indemnifying Party does not assume the defense of
     the claim, the indemnified Party may defend the claim at the indemnifying
     Party's expense. The Parties shall reasonably cooperate in the defense of
     the claim and neither Party shall settle or compromise the claim without
     the prior written consent of the other Party, which consent shall not be
     unreasonably refused or delayed.

                                       14

<PAGE>

20.  Insurance. From the Effective Date, Gambro and Dendreon shall each maintain
     comprehensive general liability, property and casualty insurance providing
     commercially reasonable coverage for their respective equipment, premises
     and businesses. From the Commencement Date, the Parties shall maintain the
     following insurance. Gambro shall maintain professional liability for each
     Site in amounts that are customary in the industry and that are no less
     than $1 million per occurrence and $3 million aggregate per site. Should
     such professional liability insurance be on a claims made basis then Gambro
     shall maintain such insurance in force for at least five (5) years
     following the end of the Term or Renewed Term or shall maintain tail
     insurance coverage for at least five (5) years following the end of the
     Term or Renewed Term. Dendreon shall maintain errors and omissions coverage
     in amounts that are customary in the industry and that are no less than $ 1
     million per occurrence and $3 million aggregate per policy. Dendreon shall
     further maintain products liability coverage in amounts that are customary
     in the industry and no less than $5 million per occurrence and $5 million
     aggregate. Should such products liability coverage be on a claims made
     basis then Dendreon shall maintain such insurance in force for at least
     five (5) years following the end of the Term or Renewed Term or shall
     maintain tail insurance coverage for at least five (5) years following the
     end of the Term or Renewed Term. The insurances polices obtained by the
     Parties shall be with financially strong insurance carriers (AM Best Rating
     of "A"V or higher). Each Party shall cause its insurance policies to be
     endorsed to provide for thirty (30) days prior written notice to the other
     by the insurance carrier of cancellation, expiration or modification of the
     insurance policy. Each Party will furnish to the other certificates of
     insurance evidence the foregoing on or before the Commencement Date.

21.  Independent Contractor. Gambro and Dendreon intend to act and perform as
     independent contractors, and the provisions of this Agreement are not
     intended to create any partnership, joint venture, agency or employment
     relationship between the parties. Each Party shall be solely responsible
     for and shall comply with all state and federal laws pertaining to
     employment taxes, income tax withholding, unemployment compensation
     contributions, and other employment related statutes applicable to that
     Party.

22.  Non-Debarment Certification. Gambro certifies that it is not debarred under
     the Federal Food, Drug and Cosmetic Act, and that it will not knowingly use
     the services of any debarred person with respect to services under this
     Agreement, and that it will amend this certification in light of new
     information.

23.  Confidential Information. Each Party will maintain the confidentiality of
     the Confidential Information of the other. The confidentiality obligations
     shall not apply to information that is subject to one or more of the
     following circumstances:

          a.   the information is now, or hereafter becomes, through no act or
               failure to act on the part of the recipient, generally known or
               available to the public;

                                       15

<PAGE>

          b.   the information is known by the recipient before it received the
               information;

          c.   the information is furnished to the recipient by a third party
               who did not acquire the information directly or indirectly from
               the disclosing Party;

          d.   the information is independently developed by the recipient
               without use or knowledge of the confidential information; or

          e.   the information is required by law or by order of any court or
               governmental authority to be disclosed by the recipient.

     In the event of such compulsory disclosure, however, the recipient shall
     give the disclosing Party sufficient advance written notice to enable it to
     seek a protective order or other remedy to protect such confidential
     information. The recipient may disclose only the minimum confidential
     information required to be disclosed, whether or not a protective order or
     other remedy is in place.

     Each Party will ensure that their employees and designees who receive
     access to the Confidential Information of the other Party are legally
     obligated to maintain the confidentiality of such Confidential Information
     and shall be responsible for the compliance of such employees and
     designees.

24.  Dispute Resolution and Governing Law.

     24.1 Informal Resolution. Should any dispute between the parties arise
          under this Agreement, Dendreon and Gambro, through appropriately
          senior persons, shall first meet and attempt to resolve the dispute in
          face-to-face negotiations. This meeting shall occur within thirty days
          of the time the dispute arises.

     24.2 Resolution Through Mediation. If no resolution is reached, Dendreon
          and Gambro shall, within forty-five days of the first meeting, attempt
          to settle the dispute by formal mediation. If the Parties cannot agree
          upon a mediator and the place of the mediation, the mediation shall be
          administered by the American Arbitration Association in Seattle,
          Washington.

     24.3 Resolution Through Arbitration. If no resolution is reached in
          mediation, the dispute shall be resolved by binding arbitration before
          a three-arbitrator panel, administered by the American Arbitration
          Association, with limited discovery.

     24.4 Venue and Governing Law. The venue and the governing law shall be
          either in and that of Seattle, Washington and the State of Washington,
          without giving effect to conflict of law considerations, or Lakewood,
          Colorado and the state of Colorado, without giving effect to conflict
          of law considerations, at the instance of the Party which is the
          respondent in the notice of intent to arbitrate.

                                       16

<PAGE>

     24.5 Equitable Relief. Notwithstanding the foregoing dispute resolution and
          governing law provisions, Dendreon and Gambro shall each retain the
          right to seek judicial injunctive and other equitable relief where
          appropriate. In no event shall punitive damages or attorney's fees be
          awardable.

25.  Force Majeure. Either Party shall be excused from performing its
     obligations under this Agreement if its performance is delayed or prevented
     by any event beyond such Party's reasonable control including, but not
     limited to terrorist acts, acts of God, fire, explosion, weather, disease,
     war, insurrection, civil strife, riots or power failure. Performance shall
     be excused, however, to the extent of and during such disability. Gambro
     will promptly notify Dendreon if, by reason of any of the events referred
     to above, Gambro is unable to meet its obligations under this Agreement at
     any of its sites.

26.  Medical Practice. Dendreon and Gambro agree that Gambro shall retain the
     sole authority to direct the medical, professional, and ethical aspects of
     its performance under this Agreement. The Parties agree that the payments
     to be made to Gambro and the services received by Dendreon under this
     agreement reflect fair market value and the benefits to Gambro and Dendreon
     hereunder do not require, are not payment or inducement for, and are in no
     way contingent upon the referral of any patient.

27.  Patient Records. Gambro shall own all patient medical records prepared by
     it and shall maintain such records during the Term and any Renewed Term and
     for a period of five (5) years thereafter or such longer period as may be
     then required by cGTP or other law or regulations. At all times, access by
     Dendreon or by any third party to patient records shall be governed by
     applicable state and federal laws governing confidentiality of patient
     records.

28.  No Obligation to Third Parties. None of the obligations and duties of
     Gambro or Dendreon under this Agreement shall in any way or in any manner
     be deemed to create any obligation of Gambro or Dendreon to, or any rights
     in, any person or entity not a Party to this Agreement.

29.  Use of Names, Dendreon Technology and Trademarks.

     29.1 Neither Party shall use the name of the other Party or the names of
          the employees of the other Party in any advertising or sales
          promotional material or in any commercial publication in a manner
          designed to promote sales of services or products without the prior
          written permission of such Party. No right, express or implied, is
          granted by this Agreement to use in any manner the "Dendreon" or
          "Gambro" or any other trade name or trademark of the other Party in
          connection with the performance of the Agreement.

                                       17

<PAGE>

     29.2 Nothing in this Agreement express or implied constitutes a grant,
          transfer, license or right of any kind in or to the Dendreon
          Technology or the Gambro Technology.

     29.3 Gambro Healthcare shall promptly and fully disclose to Dendreon any
          and all inventions, improvements, discoveries or any intellectual
          property ("Intellectual Property") conceived, developed or reduced to
          practice by Gambro Healthcare, its employees or employees of its
          affiliates in connection with, or as a result of, the services
          performed for Dendreon pursuant to the terms of this Agreement, as
          such relates to Dendreon Technology.

     29.4 Any such Intellectual Property that relates to Dendreon Technology
          shall be the proprietary and confidential information of Dendreon and
          Dendreon shall have all rights therein, including, but not limited to,
          all trade secret rights and the right to seek patent protection.

     29.5 Gambro Healthcare shall execute such documents as Dendreon may
          reasonably request and perform such other acts as Dendreon may
          reasonably request that may be necessary to fully vest Dendreon with
          ownership of said Intellectual Property which relates to Dendreon
          Technology.

     29.6 Any such Intellectual Property that relates to Gambro Healthcare
          Technology shall be the proprietary and confidential information of
          Gambro Healthcare and Gambro Healthcare shall have all rights therein,
          including, but not limited to, all trade secret rights and the right
          to seek patent protection.

     29.7 Dendreon shall execute such documents as Gambro Healthcare may
          reasonably request and perform such other acts as Gambro Healthcare
          may reasonably request that may be necessary to fully vest Gambro
          Healthcare with ownership of said Intellectual Property that relates
          to Gambro Healthcare Technology.

30.  Publication. Gambro shall not publish or present the data from or the
     results of studies carried out by it that include or are based upon data
     from cell collections under this Agreement without the express written
     consent of Dendreon.

31.  Assignment. Neither Party shall assign any of its rights and obligations
     hereunder except (i) to an Affiliate, (ii) incident to the merger,
     consolidation, reorganization or acquisition of stock affecting actual
     voting control or a sale of substantially all of the assets of the
     assigning Party or (iii) Dendreon may assign this Agreement to a third
     party engaged in the marketing, promotion or sale of Vaccines. This
     Agreement shall be binding upon and inure to the benefit of the Parties
     hereto and their permitted successors and assigns.

                                       18

<PAGE>

32.  Notices. All notices and other communications hereunder shall be in writing
     and shall be deemed given if delivered personally or by facsimile
     transmission (receipt verified), telexed, mailed by registered or certified
     mail (return receipt requested), postage prepaid or sent by express courier
     service, to the Parties at the following addresses (or such other address
     for a Party as shall be specified by like notice; provided, that notices of
     a change of address shall be effective only upon receipt.

                  If to Dendreon, addressed to:

                  T. Dennis George
                  Senior Vice President and General Counsel
                  Dendreon Corporation
                  3005 First Avenue
                  Seattle, Washington 98121

                  With copy to:

                  [Relationship Manager]
                  Dendreon Corporation
                  3005 First Avenue
                  Seattle, Washington 98121

                  If Gambro addressed to:

                  Ella Friedman
                  Gambro Healthcare, Inc.
                  10810 W. Collins Ave.
                  Lakewood, Colorado 80215

                  With copy to:

                  Gambro Healthcare, Inc.
                  Attn:  General Counsel
                  10810 W. Collins Ave.
                  Lakewood, Colorado 80215

33.  Waiver. Except as specifically provided for herein, the waiver from time to
     time by either of the Parties of any of their rights or their failure to
     exercise any remedy shall not operate or be construed as a continuing
     waiver of the same or of any other of such Party's rights or remedies
     provided in this Agreement.

34.  Ambiguities. Ambiguities, if any, in this Agreement shall not be construed
     against any Party, irrespective of which Party may be deemed to have
     authored the ambiguous provision.

                                       19

<PAGE>

35.  Entire Agreement. This Agreement and its appendices referenced herein set
     forth all of the covenants, promises, agreements, warranties,
     representations, conditions and understandings of the Parties hereto with
     regard to the subject matter in this Agreement and supersedes and
     terminates all prior agreements and understandings between the Parties with
     respect to the subject matter discussed. There are no covenants, promises,
     agreements, warranties, representations, conditions or understandings,
     either oral or written, between the Parties with regard to the subject
     matter of this Agreement other than as set forth herein. The Parties
     acknowledge that they have entered into an agreement for cell collection
     for clinical trials sponsored by Dendreon and a confidentiality agreement.
     Those agreements are deemed to address different subject matters than this
     Agreement and are not subject to this Section 35.

36.  Amendment and Modification. This Agreement may be amended or modified only
     a written document signed by authorized officers of each Party.

37.  Public Announcement and Disclosure of Terms of Agreement. Promptly after
     the Effective Date, the Parties shall issue a joint press release
     announcing this Agreement and the relationship between them. The press
     release shall be drafted by Dendreon, and shall be approved by both Parties
     prior to issuance.

38.  Confidentiality. The Parties shall keep the terms and conditions of this
     Agreement confidential except (i) as authorized in Section 37, (ii) for
     disclosures required by applicable securities laws, FDA statutes or rules
     or other laws applicable to Dendreon's Vaccines; (iii) for disclosures made
     to a third party to a proposed or consummated business transaction or
     relationship so long as the third party agrees to maintain the information
     as confidential, and (iv) for disclosures made in connection with a public
     or private equity or other financing or corporate transaction such as a
     merger, acquisition, consolidation or asset transfer so long as any third
     party participants agree to maintain the information as confidential.

39.  Survival. Sections 9, 10 11, 12, 17, 18, 19, 20, 23, 24, 27, 29 and 38
     shall survive the expiration or earlier termination of this Agreement for a
     period of ten (10) years.

40.  Counterparts. This Agreement may be executed (including by facsimile
     transmission) in any number of counterparts, each of which shall be an
     original, and all such counterparts shall together constitute but one and
     the same Agreement.

                                       20

<PAGE>

DENDREON CORPORATION                        GAMBRO HEALTHCARE, INC.

By /s/ Christopher S. Henney                By /s/ Ella Friedman
Its CEO                                     Its Senior Vice President

Date 10/26/01                               Date 10/23/01

                                            Approved as to form:

                                            By /s/ Bruce Winsor
                                            Its General Counsel

                                            Date 10/23/01

                                       21

<PAGE>

                                   Appendix E
<TABLE>
<S>                         <C>                      <C>                        <C>                      <C>
Little Rock, AK             Birmingham, AL           Phoenix, AZ                Tucson, AZ                Roseville, CA

San Francisco, CA           Fresno, CA               Los Angeles, CA            San Diego, CA             Denver, CO

Hartford, CT                Washington DC            Morton, PA                 St. Mary's, GA            Tallahassee, FL

Orlando, FL                 Tampa, FL                Miami, FL                  Atlanta, GA               Des Moines, IA

Boise, ID                   Chicago, IL              Indianapolis, IN           Wichita, KS               Louisville, KY

New Orleans, LA             Boston, MA               Baltimore, MD              Portland, ME              Detroit, MI

Wyoming, MI                 Minneapolis, MN          St. Louis, MO              Kansas City, MO           Jackson, MS

Missoula, MT                Charlotte, NC            Durham, NC                 Woburn, MA                East Orange, NJ

Albuquerque, NM             Las Vegas, NV            New York, NY               Albany, NY                Rochester, NY

Cincinnati, OH              Columbus, OH             Madison, OH                Oklahoma City, OK         Salem, OR

Philadelphia, PA            Pittsburgh, PA           Hopedale, MA               Columbia, SC              Nashville, TN

Memphis, TN                 Houston, TX              San Antonio, TX            Dallas, TX                Salt Lake City, UT

Richmond, VA                Spokane, WA              Seattle, WA                Milwaukee, WI             Charleston, WV

Portsmouth, VA
</TABLE>

<PAGE>

                                   Appendix F

                                   [...***...]

                                               *Confidential Treatment Requested

<PAGE>

                                   Appendix G

                              Performance Standards

Scheduling and Timing

     Scheduling. At each Site, Gambro shall maintain, during each calendar year,
staffing, hours, and equipment such that ninety percent (90%) of patients
referred to that Site can receive an appointment for a cell collection within
three (3) working days of their request for an appointment. The compliance
percentage shall be determined by the total number of cell collection
appointments at each Site as the denominator and the total number of
appointments scheduled within three (3) working days as the numerator. A request
by Dendreon to schedule an appointment more then three (3) working days later
shall be excluded from both the denominator and the numerator in calculating the
compliance percentage.

The noncompliance assessment for failure of a Site to meet this standard shall
be [...***...] of the total fees paid by Dendreon for cell collection at that
Site during the calendar year.

     Timely Collection. At each Site and for each calendar year, ninety five
percent (95%) of patients who appear for cell collection by the scheduled time
and for whom the cell collection is then medically appropriate will have the
procedure or patient-specific preparatory work begin no later than ten (10)
minutes after the scheduled time.

The noncompliance assessment for failure of a Site to meet this standard shall
be [...***...] of the total fees paid by Dendreon for cell collection at that
Site during the calendar year.

     Release. At each Site and for each calendar year, ninety-eight percent
(98%) of cell collections are released for transfer to a cell processing center
within thirty (30) minutes of completion of the cell collection.

The noncompliance assessment for failure of a Site to meet this standard shall
be [...***...] of the total fees paid by Dendreon for cell collection at that
Site during the calendar year.

Facilities

     Inspections. No Site shall receive more than two citations for major
quality or compliance problems or more than four citations for non-major quality
or compliance problems following any inspection performed by the FDA or
Dendreon. The classification of major quality or compliance problems shall be
made in accordance with customary FDA or industry practice, as the case may be.
The noncompliance assessment shall be [...***...] of fees paid for cell
collections performed at the affected Site during

                                               *Confidential Treatment Requested

<PAGE>

the twelve months preceding the inspection and [...***...] of fees due
thereafter until Gambro certifies to the reasonable satisfaction of Dendreon
that all quality or compliance problems noted in the inspection report have been
corrected.

     Parking. Ninety percent (90%) of Sites shall have properly posted handicap
parking and shall be wheelchair accessible. The noncompliance assessment for
parking violation shall be a [...***...] reduction of Services fees payable to
Gambro until such time as the ninety percent (90%) threshold met.

Records--Timeliness and Accuracy

     The following records required to release and track each cell collection
shall be timely prepared and completely accurate in all material respects: (i)
leukaphereis procedure report and release checklist (or like record); and (ii)
bar coding and other lot number and tracking system controls. Failure to achieve
this standard with respect to 98% percent of cell collections during a calendar
year shall reduce the total fees payable to Gambro for cell collections during
that calendar year by [...***...].

Staffing Ratios

     In those states in which technicians or other non-licensed personnel may,
consistent with state law and applicable medical standards, perform cell
collections under the supervision of a registered nurse, Gambro shall maintain
staffing ratios of one supervising licensed registered nurse to no more than two
technicians performing cell collections at any given time. This ratio shall be
maintained or exceeded for 95% of the cell collections performed at the relevant
Sites during a calendar year. The assessment for failure to achieve this
standard shall be [...***...] of the fees paid for cell collections at the
affected Site for the calendar year. Each Site employing technicians to perform
cell collections shall, by written certification signed by its Medical Director,
identify the cell collections for which this standard was not met within thirty
(30) days of the end of each calendar quarter.

Email Service/Communications

     With respect to scheduling cell collections, billing and payment and such
other administrative and operational matters as the parties shall agree upon
from time to time, if email is the primary means of communication, the elapsed
time between the time an email from Dendreon is received by Gambro during normal
business hours and the time a substantive response is sent shall average no more
than two (2) business hours over a calendar year. If telephone and pager systems
are the primary means of communication, then the parties shall in good faith
negotiate a commercially reasonable standard response time.

The noncompliance assessment for failure to adhere to this standard shall be
[...***...] of the total fees payable to Gambro for the calendar year.

                                               *Confidential Treatment Requested

<PAGE>

Patient Service

     Dendreon and Gambro shall not receive complaints from patients or
physicians about any aspect of the Services provided by Gambro that is greater
than five percent (5%) of the total number of patients (not cell collections)
performed in a calendar year. For purposes of this standard, "complaint" means a
reasonably objective negative remark about the quality of service provided by
Gambro that is written (including email) by or on behalf of a patient or by a
patient's physician, or delivered orally to Dendreon or Gambro and
contemporaneously recorded. Follow up or action upon a complaint that generates
a written document is not an additional complaint. A complaint about failure by
Gambro to follow up or take action upon a complaint is an additional complaint
for purposes of this standard.

The noncompliance assessment for failure to adhere to this standard shall be
[...***...] of the total fees paid to Gambro for the calendar year.

Interim and Final Data and Assessment of Noncompliance Fees

     Within forty five (45) days of each June 30 and December 31 during the Term
and Renewed Term, Dendreon shall provide Gambro with a report pertaining to each
of the above standards for the first two and last two calendar quarters,
respectively. The report for the last two calendar quarters also shall include a
calendar year report. The calendar year report shall notify Gambro of the
noncompliance fees, if any, due and owing for the calendar year. Noncompliance
fees, if any, shall be credited against Service fees due to Gambro thereafter
until paid in full.

     Within thirty (30) days of receipt of each report, Gambro shall notify
Dendreon of its objections, if any, to the report. The parties shall then
promptly meet to informally resolve any such objections. If they are unable to
resolve all objections either party may then invoke the dispute resolution
provisions of Section 22.

                                               *Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]